HHS Announces Wind-Down of mRNA Vaccine Development Activities

Strategic Insights -

The U.S. Department of Health and Human Services (HHS) has announced the beginning of a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA). This decision comes after a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency. HHS Secretary Robert F. Kennedy, Jr. stated that the data show mRNA vaccines fail to protect effectively against upper respiratory infections like COVID and flu, leading the department to shift funding toward safer, broader vaccine platforms.

Key Takeaways:

  • The wind-down affects 22 mRNA vaccine development investments worth nearly $500 million.
  • HHS has terminated contracts with Emory University and Tiba Biotech, and has de-scoped mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus.
  • The department has rejected or canceled multiple pre-award solicitations, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others.
  • Collaborations with DoD-JPEO will be restructured, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca, HDT Bio, and Moderna/UTMB.
  • HHS has instructed its partner, Global Health Investment Corporation (GHIC), to cease all mRNA-based equity investments.
  • The move signals a broader shift in federal vaccine development priorities, focusing on platforms with stronger safety records and transparent clinical and manufacturing data practices.
  • The wind-down does not impact other uses of mRNA technology within the department.
  • HHS Secretary Robert F. Kennedy, Jr. emphasized that the department supports safe, effective vaccines for every American who wants them.

Statistics:

  • 22 mRNA vaccine development investments worth nearly $500 million will be terminated.
  • Contracts with Emory University and Tiba Biotech will be terminated.
  • De-scaling of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus will occur.
  • Multiple pre-award solicitations, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others, will be rejected or canceled.
  • $500 million will be freed up for alternative vaccine development platforms.
  • The wind-down will affect 22 projects.

Sources:

  • U.S. Department of Health and Human Services